# ACetazolamide in Patients With Heart Failure, to Decrease Weight and relIEVE Symptoms.

Study · id `cardio:ct-nct07737964` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07737964](<https://clinicaltrials.gov/study/NCT07737964>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07737964

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 366 participants.

## Technical summary

Registry record NCT07737964. Randomized; no masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2029-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 366 participants (planned count; ClinicalTrials.gov record NCT07737964, source copy `cardio:ctgov-nct07737964-2026-08-17`, retrieved 2026-10-26)
- Planned start: 2026-10 (anticipated) (ClinicalTrials.gov record NCT07737964, source copy `cardio:ctgov-nct07737964-2026-08-17`, retrieved 2026-10-26)
- Primary completion: 2029-01 (anticipated) (ClinicalTrials.gov record NCT07737964, source copy `cardio:ctgov-nct07737964-2026-08-17`, retrieved 2026-10-26)
- Completion: 2029-01 (anticipated) (ClinicalTrials.gov record NCT07737964, source copy `cardio:ctgov-nct07737964-2026-08-17`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT07737964, source copy `cardio:ctgov-nct07737964-2026-08-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07737964-2026-08-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: ACetazolamide in Patients With Heart Failure, to Decrease Weight and relIEVE Symptoms.
- Acronym: ACHIEVE
- Condition: Heart Failure
- Intervention (Drug): Acetazolamide
- Intervention (Drug): Furosemide
- Lead sponsor: University Hospital, Montpellier
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: University Hospital, Montpellier (`cardio:org-university-hospital-montpellier`)

## Provenance

Content hash: a8578ea25558e02edb030b0641e31da824f504073b4fa580afd71361fe63a538
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
